Omega's Exit Strategy: What Alumis' Surge Means for Biotech's Future The recent SEC filing by Omega Fund Management reveals a significant dynamic within the biotechnology sector, where even major investors are forced to reassess their positions in response to a company's extraordinary growth.
The sale of 411,968 shares of Alumis (NASDAQ:ALMS) by Omega amounts to $10.
3 million, but what does this transaction say about the state of investment in biotech and the challenges facing Alumis as it prepares for its next phase?